IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease

Autoimmunity Reviews

Volumn 14, Issue 5, 2015, Pages 370-375

  Touzot, Maxime ^a,b   Cacoub, Patrice ^c,d   Bodaghi, Bahram ^c   Soumelis, Vassili ^a,b   Saadoun, David ^c,d  

^a PSL RESEARCH UNIVERSITY   (France)

^b INSTITUT CURIE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Beh et's disease; IL 10; Interferon; Systemic lupus erythematosus; T helper cells

Indexed keywords

ALPHA INTERFERON; CD45RO ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPERNATANT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH1 TH17 BALANCE; TH17 CELL; TH2 CELL; YOUNG ADULT; BIOSYNTHESIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY;

BEHCET SYNDROME; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-ALPHA; INTERLEUKIN-10; TH1 CELLS; TH17 CELLS;

EID: 84925160994     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.009     Document Type: Review

References (36)

1. Mizuki N., Meguro A., Ota M., Ohno S., Shiota T., Kawagoe T., et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010, 42:703-706.
2. Remmers E.F., Cosan F., Kirino Y., Ombrello M.J., Abaci N., Satorius C., et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010, 42:698-702.
3. Geri G., Terrier B., Rosenzwajg M., Wechsler B., Touzot M., Seilhean D., et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011, 128:655-664.
4. Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behcet's disease. Autoimmun Rev 2012, 11:699-704.
5. Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev 2014, 13:591-594.
6. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
7. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990.
8. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010, 207:2053-2063.
9. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
10. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
11. Ronnblom L., Alm G.V., Eloranta M.L. Type I interferon and lupus. Curr Opin Rheumatol 2009, 21:471-477.
12. Gualtierotti R., Biggioggero M., Penatti A.E., Meroni P.L. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2010, 10:3-7.
13. Touzot M., Grandclaudon M., Cappuccio A., Satoh T., Martinez-Cingolani C., Servant N., et al. Combinatorial flexibility of cytokine function during human T helper cell differentiation. Nat Commun 2014, 5:3987.
14. Wong M.T., Ye J.J., Alonso M.N., Landrigan A., Cheung R.K., Engleman E., et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol 2010, 88:624-631.
15. Dikopoulos N., Bertoletti A., Kroger A., Hauser H., Schirmbeck R., Reimann J. Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol 2005, 174:99-109.
16. Moschen A.R., Geiger S., Krehan I., Kaser A., Tilg H. Interferon-alpha controls IL-17 expression in vitro and in vivo. Immunobiology 2008, 213:779-787.
17. Hirohata S., Shibuya H., Tejima S. Suppressive influences of IFN-α on IL-17 expression in human CD4+ T cells. Clin Immunol 2010, 134:340-344.
18. Tanrikulu L. Scoring of international criteria for Behçet's disease. J Eur Acad Dermatol Venereol 2014, [Epub ahead of print].
19. Criteria for diagnosis of Behçet's disease International Study Group for Behçet's Disease. Lancet 1990, 335:1078-1080.
20. Cervera R., Espinosa G. Connective tissue diseases: classification criteria for SLE: the latest-but not least-attempt. Nat Rev Rheumatol 2012, 8:506-507.
21. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639-646.
22. Wang Y.-H., Ito T., Wang Y.-H., Homey B., Watanabe N., Martin R., et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 2006, 24:827-838.
23. Sinigaglia F., D'Ambrosio D., Rogge L. Type I interferons and the Th1/Th2 paradigm. Dev Comp 1999, 23.
24. Liu X., Yang P., Wang C., Li F., Kijlstra A. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease. Rheumatology (Oxford) 2011, 50:293-298.
25. Kühn R., Löhler J., Rennick D., Rajewsky K., Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
26. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
27. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181.
28. Hamzaoui K., Hamzaoui A., Guemira F., Bessioud M., Hamza M., Ayed K. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002, 31:205-210.
29. Ronnblom L., Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008, 17:394-399.
30. Axtell R.C., De Jong BA, Boniface K., Van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon- in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
31. Malhotra S., Bustamante M.F., Perez-Miralles F., Rio J., de Villa MC Ruiz, Vegas E., et al. Search for specific biomarkers of IFNbeta bioactivity in patients with multiple sclerosis. PLoS One 2011, 6:e23634.
32. Chen M., Chen G., Deng S., Liu X., Hutton G.J., Hong J. IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol 2012, 242:39-46.
33. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009, 183:5418-5427.
34. Malucchi S., Gilli F., Caldano M., Marnetto F., Valentino P., Granieri L., et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008, 70:1119-1127.
35. Zhang L., Yuan S., Cheng G., Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One 2011, 6:e28432.
36. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686.